Drug Trial Radar · NCT07835581
Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
620
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Mar 2029
Study completion Mar 2033
Sponsor
- Lead sponsor
- Eledon PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult participants undergoing first kidney transplantation.
Conditions
- Kidney Transplant Rejection
Interventions
TegoprubartDrug
Tegoprubart administered via IV infusion
TacrolimusDrug
Tacrolimus administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy failure rate at 12 months post-transplant, defined as the first occurrence of biopsy proven acute rejection, graft loss, or deathTime frame: 12 months post-transplant
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.